These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 27282563

  • 1. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
    Berzoti-Coelho MG, Ferreira AF, de Souza Nunes N, Pinto MT, Júnior MC, Simões BP, Martínez-A C, Souto EX, Panepucci RA, Covas DT, Kashima S, Castro FA.
    Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
    [Abstract] [Full Text] [Related]

  • 2. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y, Fang F, Hu Y, Liu Q, Bu D, Tan M, Wu L, Zhu P.
    PLoS One; 2016 Jul; 11(4):e0154183. PubMed ID: 27111338
    [Abstract] [Full Text] [Related]

  • 3. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Jul; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 4. [Analysis of Clinical Characteristics of JAK2 V617F and BCR-ABL Double-Mutant Myeloproliferative Neoplasms].
    Yan J, Ding YW, Wang PY, Wu YP, Zhang HC, Liu LH.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1540-1547. PubMed ID: 34627437
    [Abstract] [Full Text] [Related]

  • 5. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Oct; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 6. Rare Case of Accelerated-Phase Chronic Myeloid Leukemia Diagnosed During Treatment for JAK2 V617F-Positive Primary Myelofibrosis.
    Ryu J, Chu D, Park B, Kim M, Cho YU, Hwang SH, Jang S, Seo EJ, Lee JH, Park CJ.
    Lab Med; 2022 Nov 03; 53(6):e140-e144. PubMed ID: 35243502
    [Abstract] [Full Text] [Related]

  • 7. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K, Shimoda K.
    Rinsho Byori; 2009 Apr 03; 57(4):357-64. PubMed ID: 19489438
    [Abstract] [Full Text] [Related]

  • 8. A case of double positive myeloproliferative neoplasm: A diagnostic and therapeutic challenge.
    Shaikh AB, Aribandi A, Gupta A, Subramanian SK, Goyal M.
    Indian J Pathol Microbiol; 2021 Apr 03; 64(4):820-823. PubMed ID: 34673614
    [Abstract] [Full Text] [Related]

  • 9. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM, Bagg A.
    Int J Lab Hematol; 2015 May 03; 37 Suppl 1():61-71. PubMed ID: 25976962
    [Abstract] [Full Text] [Related]

  • 10. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS, Kim YK, Jung SI, Jung HR, Chung IS.
    Ann Lab Med; 2012 Nov 03; 32(6):385-91. PubMed ID: 23130336
    [Abstract] [Full Text] [Related]

  • 11. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases.
    Vainchenker W, Constantinescu SN.
    Hematology Am Soc Hematol Educ Program; 2005 Nov 03; ():195-200. PubMed ID: 16304380
    [Abstract] [Full Text] [Related]

  • 12. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.
    Eur J Haematol; 2007 Dec 03; 79(6):508-15. PubMed ID: 17961178
    [Abstract] [Full Text] [Related]

  • 13. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
    Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders.
    Blood Cells Mol Dis; 2007 Dec 03; 49(3-4):170-6. PubMed ID: 22818858
    [Abstract] [Full Text] [Related]

  • 14. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.
    Korean J Lab Med; 2010 Dec 03; 30(6):567-74. PubMed ID: 21157140
    [Abstract] [Full Text] [Related]

  • 15. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.
    Br J Haematol; 2016 Jul 03; 174(2):218-26. PubMed ID: 27061303
    [Abstract] [Full Text] [Related]

  • 16. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.
    Thromb Res; 2014 Feb 03; 133(2):218-21. PubMed ID: 24309205
    [Abstract] [Full Text] [Related]

  • 17. Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
    Tefferi A.
    Am J Hematol; 2016 Jan 03; 91(1):50-8. PubMed ID: 26492355
    [Abstract] [Full Text] [Related]

  • 18. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
    Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.
    Diagn Mol Pathol; 2012 Sep 03; 21(3):176-83. PubMed ID: 22847163
    [Abstract] [Full Text] [Related]

  • 19. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, de Cesare Quintero F, Pagliari-E-Silva S, Pagnano KB, Rodrigues C, de Alencar JB, Sell AM, Visentainer JE.
    Blood Cells Mol Dis; 2016 Mar 03; 57():54-7. PubMed ID: 26852656
    [Abstract] [Full Text] [Related]

  • 20. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.
    Clin Lymphoma Myeloma Leuk; 2014 Dec 03; 14(6):525-33. PubMed ID: 24811089
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.